Menu +

Korlym® selected Brand of the Year by Pharmaceutical Executive

Korlym® (mifepristone) 300mg Tablets has been selected by Pharmaceutical Executive as 2014 Brand of the Year, representing clinical and marketing achievements for an orphan-status rare disease drug. In selecting Korlym, Pharmaceutical Executive looked for a medicine that combines three strengths:

  • A novel clinical profile
  • An advance in the state of care for a difficult to treat condition, affecting a neglected cohort of patients
  • Distinctive, multi-channel marketing geared to building community awareness around the disease, not the product

Since Korlym’s launch in 2012, Corcept has focused on building relationships with patients, endocrinologists and the Cushing’s community. Our dedicated Patient Advocate Program is one of the key programs that connects with and supports patients throughout their journey. More information for patients and prescribers is available at

“Korlym is the first step toward a business that we are creating around a unifying scientific theme, which is to understand how excess cortisol levels influence the incidence and progression of not just one, but potentially dozens, of different conditions,” Corcept CEO Joe Belanoff told Pharmaceutical Executive.

Indications and Usage

Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Important Limitations of Use

Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.


Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.

Please see Full Prescribing Information and Medication Guide.

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue